{"id":1171033,"date":[{"year":1998,"month":10,"day":8}],"page":"13","source":"","region":"","masthead":"广告","special_issue":"文汇报样样有(第41期)","column":"","genre":"","count":"264","ytitle":"","mtitle":"乳腺癌的口服化疗","ftitle":"","authors":[],"text":[{"type":"paragraph","text":"伦敦皇家马斯登医院的IanSmith在第五届诺丁汉国际乳腺癌大会上说，乳腺癌口服化疗的Ⅱ期试验终于开始。"},{"type":"paragraph","text":"口服化疗比连续泵输注更容易被病人接受，但是许多抗癌药物的生物可用性不能预测而且生手学半衰期短，妨碍了口服治疗的发展。Smith小组正在直行联用5-乙炔尿嘧啶和5-氟尿嘧啶(5-FU)的试验。他们已经发现此方法有临订反且素毒性较低。Smith指出，输注化疗治疗乳腺癌的效能很高，下一步是口服5-FU衍生物。他预测，“在一年内”输注泵可能开始被逐步淘汰。"},{"type":"paragraph","text":"由《抗癌》杂志和《抗癌》动态刊副社长　责任编辑秦孟家供稿"}]}